These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32879847)

  • 1. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India.
    Vaswani B; Bhagat S; Patil S; Barkate H
    World J Clin Oncol; 2020 Aug; 11(8):606-613. PubMed ID: 32879847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
    Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K
    Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies.
    Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V
    Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed-dose combination to prevent chemotherapy-induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy.
    Md Yusof M; Abdullah MM; Yap BK; Ng SC; Low JSH; Lam KS; Ahmad Badruddin RBA; Lai CNB; Lau KL; Chong KJ; Nonis JG; Ahmad Annuar MA; Abdul Rahman MHFB
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):419-427. PubMed ID: 34811924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
    Navari RM
    Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.
    Cawston H; Bourhis F; Eriksson J; Ruffo P; D'Agostino P; Turini M; Schwartzberg L; McGuire A
    Drugs Context; 2017; 6():212298. PubMed ID: 28392826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Evaluation of a Dexamethasone Sparing Antiemetic Regimen: An Antiemetic Prophylaxis Study on NEPA (Netupitant Plus Palonosetron) for Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients.
    Agre S; Agre M; Pol P; Tonse M; Mohanty M; Shaikh A
    Cureus; 2023 Nov; 15(11):e49763. PubMed ID: 38161895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Park SH; Binder G; Corman S; Botteman M
    J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
    [No Abstract]   [Full Text] [Related]  

  • 9. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study.
    Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M
    BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients.
    Aapro M; Jordan K; Gralla RJ; Rizzi G; Rossi G; Palmas M; Alyasova AV; Lisyanskaya AS; Bošnjak SM; Hesketh PJ
    J Geriatr Oncol; 2017 Jan; 8(1):56-63. PubMed ID: 27889278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
    Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
    Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study.
    Vaswani B; Dattatreya PS; Barkate H; Bhagat SB; Patil S; Jadhav AY
    Cureus; 2022 Sep; 14(9):e29094. PubMed ID: 36259011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    Boccia R; O'Boyle E; Cooper W
    BMC Cancer; 2016 Feb; 16():166. PubMed ID: 26921245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
    Rugo HS; Rossi G; Rizzi G; Aapro M
    Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination.
    Janicki PK
    Ther Clin Risk Manag; 2016; 12():693-9. PubMed ID: 27194913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment.
    Giuliani J; Bonetti A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):505-508. PubMed ID: 31379219
    [No Abstract]   [Full Text] [Related]  

  • 17. The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting.
    Vaswani B; Dattatreya PS; Bhagat S; Patil S; Barkate H
    BMC Cancer; 2021 May; 21(1):601. PubMed ID: 34034703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
    Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.